[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369859-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369859-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","use-of-routinely-collected-health-data-england-to-identify-subsequent-disease-related-events-in-patients-with-primary-breast-cancer-a-practical-alternative-to-hospital-based-follow-up-for-breast-cancer-clinical-trials","Use of routinely collected health data (England) to identify subsequent disease-related events in patients with primary breast cancer - a practical alternative to hospital-based follow-up for breast cancer clinical trials","","Routine follow-up for breast cancer clinical trial participants has traditionally relied on hospitals, creating burdens for patients and site staff. This study develops and tests a procedure that uses routinely collected health datasets in England to identify cancer recurrence within routine data, despite historically poor recording of recurrence compared with initial diagnosis. Data from four multicentre early breast cancer trials were linked to NHS England datasets to classify recurrence events and derive time-to-recurrence, disease-free survival, and overall survival outcomes, reporting diagnostic performance and treatment effect estimates.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/use-of-routinely-collected-health-data-england-to-identify-subsequent-disease-related-events-in-patients-with-primary-breast-cancer-a-practical-alternative-to-hospital-based-follow-up-for-breast-cancer-clinical-trials/369859/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/use-of-routinely-collected-health-data-england-to-identify-subsequent-disease-related-events-in-patients-with-primary-breast-cancer-a-practical-alternative-to-hospital-based-follow-up-for-breast-cancer-clinical-trials/369859.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is long-term follow-up important for breast cancer clinical trial participants?","Question",{"text":63,"@type":64},"Because recurrence risk can persist for decades after diagnosis, long-term follow-up is needed to characterize the durability of treatment impact and detect late disease-related outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the procedure identify recurrence using routinely collected health datasets?",{"text":68,"@type":64},"It links prospective recurrence data from four early breast cancer trials to routine datasets managed by NHS England, then identifies event types using specific diagnosis and procedure coding, combining indicators to derive time-to-recurrence and survival outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"How accurate were the routine-data recurrence identification results?",{"text":72,"@type":64},"Agreement between trial and routine-data events was reasonable, specificity was high across endpoints, NPV was also high, while sensitivity and positive predictive value varied across endpoints and datasets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369859,1790220630,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Kilburn et al. Trials (2025) 26:359  \n[https://doi.org/10.1186/s13063-025-09085-1](https://doi.org/10.1186/s13063-025-09085-1)  \nTrials  \n METHODOLOGY Open Access  \nUse of routinely collected health  \ndata (England) to identify subsequent disease-related events in patients with primary breast cancer: a practical alternative to hospital-based follow-up for breast cancer clinical trials  \nLucy S. Kilburn 1* , Victoria Hinder 1, Sikhuphukile G. Mahati 1 and Judith M. Bliss 1  \nAbstract  \nBackground With continued improvements in breast cancer (BC) outcomes and risk of recurrence occurring  \nuntil at least 20 years post-diagnosis, it is important to continue to follow up clinical trial participants to characterise long-term treatment impact. Traditionally, follow-up has been via hospitals, entailing burden on patients and site staff. Using routinely collected health datasets (RCHD) as an alternative method is attractive, but historically, cancer recurrence is poorly recorded, unlike initial cancer diagnosis. Here we use data collected prospectively from large, multicentre BC clinical trials to develop and test a procedure to identify recurrence within RCHD.  \nMethods Data from four trials of early breast cancer (TACT2, POETIC, IMPORT-HIGH and FAST-Forward) where recurrence data has been collected prospectively (gold standard) was linked with RCHD (incl. cancer registry and hospital episode statistics; HES) managed by NHS England. The procedure identified episodes of clinical activity within RCHD to classify each event type (local and distant recurrence, second cancers, death) separately, then combined to derive time-to-recurrence (TTR), disease-free survival (iDFS) and overall survival (OS) outcomes. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. Hazard ratios using Cox regression modelling, log-rank test p-values, and 3-year survival rates for the randomised treatments were reported separately for RCHD and trial data.  \nResults The final procedure used Cancer Registry diagnoses to identify initial BCs for quality control purposes and second primary cancers. Deaths were identified via death dates and cause. Distant recurrence was identified predominantly by direct indicators of metastases (e. g. ICD10 codes C77X-79X) . Local recurrence was identified via relevant surgeries’ OPCS4 codes. ForTTR, iDFS and OS, agreement between study and RCHD events was reasonable. Specificity was good across all endpoints (range: 97 .9–99. 9% for three training datasets combined), as was NPV (range: 95 .2–99. 6%) . Sensitivity and PPV were more variable, with sensitivity ranging between 72.9 and 97. 2% and PPV  \n*Correspondence: Lucy S. Kilburn [Lucy.Kilburn@icr.ac.uk](Lucy.Kilburn@icr.ac.uk)  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nKilburn et al. Trials (2025) 26:359 Page 2 of 17  \nranging b","cbCaicDXyo5mQg39","https://ap.wps.com/l/cbCaicDXyo5mQg39","pdf",3526110,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Clinical follow-up needs\n## Role of randomised controlled trials\n# Methods\n## Data linkage and event classification\n## Outcome derivation and statistical evaluation\n# Results\n## Recurrence identification approach\n## Diagnostic performance and survival agreement\n# Conclusion","[{\"question\":\"Why is long-term follow-up important for breast cancer clinical trial participants?\",\"answer\":\"Because recurrence risk can persist for decades after diagnosis, long-term follow-up is needed to characterize the durability of treatment impact and detect late disease-related outcomes.\"},{\"question\":\"How does the procedure identify recurrence using routinely collected health datasets?\",\"answer\":\"It links prospective recurrence data from four early breast cancer trials to routine datasets managed by NHS England, then identifies event types using specific diagnosis and procedure coding, combining indicators to derive time-to-recurrence and survival outcomes.\"},{\"question\":\"How accurate were the routine-data recurrence identification results?\",\"answer\":\"Agreement between trial and routine-data events was reasonable, specificity was high across endpoints, NPV was also high, while sensitivity and positive predictive value varied across endpoints and datasets.\"}]","Use of routinely collected health data (England) to identify subsequent disease-related events in patients with primary breast cancer - a practical alternative to hospital-based follow-up for breast cancer clinical trials | PDF",1790184919,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46413eb80082f5231e72bb5a0d6750d4.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9bea1e0efb2d516350387e4516e05ae.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/423243d808321c58e796d3fbaded64b1.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1873817fed9c2ff3489c60189c246876.webp",980,1301]